TCRT · Alaunos Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.0K | $10.0K | $5.0K | $2.92M | $0 | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $1.36M | $362.0K | $16.28M | $25.02M | $49.64M | $52.70M |
| SG&A | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M | $27.66M |
| Total Operating Expenses | $4.23M | $4.82M | $34.27M | $38.03M | $77.95M | $80.36M |
| D&A | $7.0K | $2.0K | $2.31M | $2.76M | $2.60M | $1.13M |
| Operating Income | ($4.22M) | ($4.81M) | ($34.27M) | ($35.10M) | ($77.55M) | ($80.36M) |
| Interest Expense | - | $0 | $1.92M | $3.15M | $1.20M | - |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($4.18M) | ($4.68M) | ($35.14M) | ($37.73M) | ($78.75M) | ($79.98M) |
| EPS - Basic | ($2.20) | ($2.92) | ($22.00) | ($55.50) | - | ($57.00) |
| EPS - Diluted | ($2.20) | ($2.92) | ($22.00) | ($25.50) | - | ($57.00) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39M | $1.09M | $6.06M | $39.06M | $76.05M | $115.07M |
| Accounts Receivable | $3.0K | $5.0K | $1.0K | $4.0K | $1.11M | $4.67M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $613.0K | $516.0K | $616.0K | $1.39M | $1.37M | $960.0K |
| Current Assets | $1.99M | $2.75M | $8.26M | $53.80M | $78.83M | $130.59M |
| Total Assets | $2.97M | $2.75M | $8.26M | $64.94M | $94.86M | $146.34M |
| Current Liabilities | $813.0K | $692.0K | $1.96M | $24.17M | $16.04M | $18.37M |
| Long-term Debt | - | $0 | $0 | $0 | $16.25M | - |
| Total Liabilities | $813.0K | $692.0K | $1.96M | $26.38M | $36.81M | $22.36M |
| Stockholders' Equity | $2.15M | $2.06M | $6.31M | $38.55M | $58.06M | $123.98M |
| Retained Earnings | ($924.62M) | ($920.45M) | ($915.77M) | ($880.63M) | ($842.85M) | ($764.10M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.87M) | ($4.97M) | ($30.14M) | ($29.23M) | ($61.47M) | ($57.01M) |
| Investing Cash Flow | ($98.0K) | $0 | $1.35M | ($193.0K) | ($3.32M) | ($9.78M) |
| Financing Cash Flow | $3.26M | $0 | ($18.14M) | $6.37M | $25.78M | $102.12M |
| CapEx | $98.0K | $0 | $197.0K | $216.0K | $3.32M | $9.78M |
| Free Cash Flow | ($2.97M) | ($4.97M) | ($30.34M) | ($29.45M) | ($64.79M) | ($66.79M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -84500.0% | -48120.0% | -685340.0% | -1201.4% | - | - |
| EBITDA margin | -84360.0% | -48100.0% | -639040.0% | -1107.0% | - | - |
| Net margin | -83520.0% | -46790.0% | -702800.0% | -1291.2% | - | - |
| Free cash flow margin | -59340.0% | -49710.0% | -606780.0% | -1007.8% | - | - |
| FCF / Net income | 0.71 | 1.06 | 0.86 | 0.78 | 0.82 | 0.84 |
| R&D / Revenue | 27260.0% | 3620.0% | 325580.0% | 856.2% | - | - |
| SG&A / Revenue | 57340.0% | 44600.0% | 244380.0% | 449.8% | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -140.8% | -169.8% | -425.3% | -58.1% | -83.0% | -54.6% |
| Return on equity | -194.0% | -226.8% | -557.2% | -97.9% | -135.6% | -64.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 |
| Quick ratio | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 |
| Cash ratio | 1.70 | 1.58 | 3.10 | 1.62 | 4.74 | 6.26 |
| Leverage | ||||||
| Debt / Equity | - | 0.00 | 0.00 | 0.00 | 0.28 | - |
| Debt / Assets | - | 0.00 | 0.00 | 0.00 | 0.17 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -17.8x | -11.1x | -64.6x | - |
| Equity multiplier | 1.38 | 1.34 | 1.31 | 1.68 | 1.63 | 1.18 |
| Liabilities / Assets | 0.27 | 0.25 | 0.24 | 0.41 | 0.39 | 0.15 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 219d | 183d | 73d | 0d | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 2.9x | 1.5x | 26.6x | 542.2x | - | 639.1x |
| P / S | 1258.6x | 305.8x | 33590.2x | 7154.0x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -50.0% | 100.0% | -99.8% | - | - | - |
| Revenue CAGR (3y) | -88.0% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | -80.1% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 12.2% | 86.0% | 2.4% | 54.7% | 3.5% | -38.9% |
| Net income growth (YoY) | 10.8% | 86.7% | 6.9% | 52.1% | 1.5% | 32.1% |
| EPS growth (YoY) | 24.7% | 86.7% | 13.7% | - | - | -8042.9% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 40.3% | 83.6% | -3.0% | 54.5% | 3.0% | -62.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 4.4% | -67.3% | -83.6% | -33.6% | -53.2% | 30.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.0K totalRoyalty$5.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-267.07
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Alaunos Therapeutics against the 5 most active filers in the same SIC group.